Holen Sie sich die Stockscreener-App
2.69
1.10%
-0.03
Handel nachbörslich:
2.80
0.11
+4.09%
Schlusskurs vom Vortag:
$2.72
Offen:
$2.69
24-Stunden-Volumen:
133.71K
Relative Volume:
0.22
Marktkapitalisierung:
$43.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.4349
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
-5.28%
1M Leistung:
-9.43%
6M Leistung:
-51.36%
1J Leistung:
-86.14%
1-Tages-Spanne:
$2.58
$2.695
1-Wochen-Bereich:
$2.58
$2.87
52-Wochen-Spanne:
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.69 | 44.86M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics : Corporate Presentation September 2025 - MarketScreener
Jasper Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Clinical-Stage Biotech Jasper Therapeutics to Showcase Briquilimab Progress at Major Healthcare Conferences - Stock Titan
Health Rounds: Experimental Jasper drug helps stem cell transplant patients avoid toxic chemotherapy in tiny trial - Reuters
Jasper Therapeutics shares rise 1.71% after-hours as biotech sector growth and innovation drive investor optimism. - AInvest
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures - MSN
HC Wainwright Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q3 EPS Forecast for Jasper Therapeutics Reduced by Analyst - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - FinancialContent
UBS Group Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price - Defense World
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75 - Defense World
Jasper Therapeutics Reports Promising Q2 2025 Results - MSN
UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $12 to $25 - 富途牛牛
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline - TipRanks
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays, Competitive Pressures - AInvest
Jasper Therapeutics' Promising Clinical Data and Strategic Focus Earn Buy Rating - AInvest
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks By Investing.com - Investing.com South Africa
Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks - Investing.com
BTIG reiterates Buy rating on Jasper Therapeutics stock with $20 price target - Investing.com Canada
JMP reiterates Market Outperform rating on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Jasper Reports Wider Loss in Fiscal Q2 - AOL.com
Jasper Therapeutics shares fall 4.65% after-hours following Q2 2025 earnings report. - AInvest
Jasper Reports Wider Loss in Fiscal Q2 - The Motley Fool
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33) - TipRanks
Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest
Jasper Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jasper Therapeutics shares rise 3.51% intraday after Metagenomi reported positive business updates and financial results. - AInvest
Jasper Therapeutics under investigation for alleged securities fraud. - AInvest
Jasper Therapeutics shares rise 5.70% intraday after Metagenomi appoints Laurence Reid, PhD to its Board of Directors. - AInvest
Jasper Therapeutics Inc (JSPR) Stock: The Story of a 52-Week Stock Range - investchronicle.com
How does the Q2 2025 earnings report affect JSPR's stock price? - AInvest
Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at EF Hutton Acquisition Co. I - 富途牛牛
Jasper Therapeutics WRT JSPRW Q2 2025 Earnings Preview Downside Expected Amid Technical Integration Hurdles - AInvest
Jasper Therapeutics JSPR 2025Q2 Earnings Preview Downside Ahead on Technical Challenges and Report Compilation Errors - AInvest
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Jasper Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView
Jasper Therapeutics shares fall 3.02% intraday after Pomerantz Law Firm investigates claims of securities fraud. - AInvest
What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News
What are the latest earnings results for Jasper Therapeutics Inc.Smart Portfolio Planner With Proven Results - Jammu Links News
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Jasper Therapeutics Inc-Aktie (JSPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):